Why the study?
The study was conducted to evaluate the effect of carotid sinus nerve stimulation on the progression of cardiorenal syndrome type 1, 3 days after acute myocardial infarction.
Does carotid sinus nerve stimulation improve cardiac, renal, and inflammatory parameters in a rat model of cardiorenal syndrome type 1 after acute myocardial infarction?
Does carotid sinus nerve stimulation improve cardiac, renal, and inflammatory parameters in a rat model of cardiorenal syndrome type 1 after acute myocardial infarction?
Carotid sinus nerve stimulation attenuates early cardiac and renal dysfunction and reduces inflammatory markers in a rat model of cardiorenal syndrome type 1 following acute myocardial infarction.
Hypothesis-generating in rat cardiorenal syndrome; human trials required before any clinical consideration.
AIM: To evaluate the effect of carotid sinus nerve stimulation (CSNS) in the progression of cardiorenal syndrome type 1 (CRS1), 3 days after acute myocardial infarction (AMI). METHODS: Male rats were divided into four groups. CSNS was applied daily for 10 min over 3 days. Cardiac, renal, and inflammatory parameters characterized the CRS1 and the electroceutical effects of CSNS. RESULTS: CSNS reduced the ischemic zone compared to the AMI group not exposed to CSNS (32.7% ± 2.2% vs. 8.0% ± 1.8%). Heart rate (bpm) was increased in the AMI group, showing 440 ± 7.6 at 48 h and 428 ± 1.0 at 60 h post-AMI. Additionally, arterial pressure (mmHg) was increased in the AMI group at 48 h, as follows: mean: 98 ± 1.7, diastolic: 89 ± 2.1, and systolic: 122 ± 5.3. In contrast, the CSNS + AMI group showed significant reductions of these parameters: mean: 79 ± 2.0, diastolic, 66 ± 1.7, and systolic: 99 ± 2.7. Renal injury was confirmed by increased apoptosis in the AMI group. A significant increase in TNF-α was observed in both heart and kidneys (pg/mg of tissue) in the AMI group and reduced IL-6 and IL-1β levels in the CSNS + AMI group, indicating an attenuation of the inflammatory responses by CSNS. CONCLUSIONS: This study demonstrates early cardiac and renal dysfunction in CRS1 following AMI, associated with elevated inflammatory markers (TNF-α, IL-6, and IL-1β) and renal apoptosis. Therefore, CSNS appears to be a promising electroceutical approach for CRS1. Besides, on the basis of previous studies from our laboratory, CSNS involves stimulation of the baroreflex, activating the parasympathetic and inhibiting the sympathetic nervous system.
No takes yet. Share an insight, caveat, or question.
Cavalheiro et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: